aptamer optimization
Info Center
  • Aptamer Affinity Optimization

    Aptamer affinity optimization refers to the process of improving the binding strength and specificity of an aptamer—a short, single-stranded DNA or RNA molecule—to its target molecule (protein, small molecule, or cell surface marker). Higher affinity aptamers result in better sensitivity and selectivity in diagnostic, therapeutic, and research applications. Key Concepts Affinity vs. Specificity Affinity: How tightly an aptamer binds to its target (quantified by dissociation constant, K_d). Lower K_d indicates higher affinity. Specificity: Aptamer’s ability to distinguish the target from similar molecules. Factors Affecting Aptamer Affinity Sequence composition and length. Secondary and tertiary structures (e.g., stem-loops, G-quadruplexes). Target-binding site accessibility. Ionic conditions (Mg²⁺, Na⁺) and pH. Optimization Strategies In vitro Evolution Methods SELEX (Systematic Evolution of Ligands by EXponential enrichment) Iterative rounds of selection and amplification to enrich high-affinity sequences. Variants: High-stringency SELEX: Lower target concentrations or harsher washing steps. Counter-SELEX: Remove sequences binding to similar molecules to enhance specificity. Truncation and Structural Optimization Remove non-essential nucleotides to reduce size while retaining binding. Stabilize key secondary structures (e.g., adding stem loops or G-quadruplex motifs). Chemical Modifications 2’-Fluoro, 2’-O-methyl nucleotides: Enhance stability and sometimes affinity. PEGylation or LNA (locked nucleic acids): Improve folding and binding. Rational Design & Mutagenesis Identify and…

    2026-01-19
  • Customized Aptamer Selection

    Customized Aptamer Selection refers to a tailored process of identifying and developing aptamers—short, single-stranded DNA or RNA molecules—that specifically bind to a target molecule (proteins, small molecules, cells, or pathogens) according to a client’s specific requirements. Unlike standard aptamer screening, it focuses on individualized targets, binding conditions, and functional needs. Key Features: Target Specificity: Aptamers are selected for high affinity and specificity to a particular target. Flexible Design: Can be designed for proteins, peptides, small molecules, ions, or whole cells. Binding Conditions Customization: pH, temperature, ionic strength, or buffer system can be tailored. Functional Application: Aptamers can be developed for diagnostics, therapeutics, biosensors, or research. High-Throughput & Efficiency: Advanced techniques allow rapid screening for optimal aptamers. Typical Workflow: Target Analysis: Understanding target structure and function. Library Preparation: Generate a diverse pool of oligonucleotides. SELEX (Systematic Evolution of Ligands by EXponential enrichment): Iterative selection process to enrich high-affinity aptamers. Binding Affinity Testing: Determine Kd (dissociation constant) and specificity. Sequence Optimization & Modification: Chemical modifications for stability or functionalization. Delivery of Customized Aptamer: Ready for research, diagnostics, or therapeutic use. Common Applications: Diagnostics: Biosensors for disease markers. Therapeutics: Targeted drug delivery. Research Tools: Protein purification or molecular imaging. Environmental Monitoring: Detection of…

    2026-01-19
  • SELEX Aptamer Screening

    1. What is SELEX? SELEX stands for Systematic Evolution of Ligands by EXponential enrichment. It is a laboratory technique used to identify aptamers—short single-stranded DNA or RNA sequences that can bind specifically to a target molecule (proteins, small molecules, cells, or even viruses). Aptamers act similarly to antibodies but are synthetic, highly stable, and can be chemically modified. 2. Principle of SELEX The SELEX process is based on iterative rounds of selection and amplification: Library Preparation Start with a large randomized pool of oligonucleotides (typically 10^13–10^15 unique sequences). Each sequence is a potential aptamer candidate. Binding (Target Incubation) Incubate the library with the target molecule. Only sequences that can bind the target will stay attached; non-binders are washed away. Partitioning (Separation of Binders and Non-binders) Physically separate bound sequences from unbound sequences. Techniques depend on the target (magnetic beads, affinity columns, etc.). Elution Bound sequences are eluted (released) from the target. Amplification The eluted sequences are amplified using PCR (for DNA aptamers) or RT-PCR (for RNA aptamers). This generates an enriched pool for the next round. Iterative Rounds Steps 2–5 are repeated for 8–15 rounds to gradually enrich sequences with high affinity and specificity for the target. Sequence Identification After…

    2026-01-19
  • Pathogen SELEX Aptamer Screening Service

    What is SELEX and What are Aptamers? Aptamers: Often called "chemical antibodies," they are short, single-stranded DNA or RNA oligonucleotides that fold into specific 3D shapes to bind with high affinity and specificity to a target molecule (e.g., a viral protein, whole bacterium, or parasite surface marker). SELEX (Systematic Evolution of Ligands by EXponential enrichment): This is the iterative combinatorial chemistry process used to discover aptamers from a vast random library (10^14-10^15 unique sequences). It involves repeated cycles of: 1) Binding the library to the target, 2) Separating bound from unbound sequences, 3) Amplifying the bound sequences, and 4) Starting a new, enriched cycle. Core Components of a Pathogen SELEX Service A professional service will typically manage the entire pipeline: 1. Project Design & Target Preparation: Consultation: Defining the precise target (e.g., whole inactivated SARS-CoV-2, Salmonella outer membrane protein, Plasmodium lysate). Counter-SELEX: A critical step for pathogen specificity. The process is run against related non-targets (e.g., host cells, non-pathogenic bacterial strains) to filter out cross-reactive aptamers, ensuring the final aptamers distinguish between pathogen and non-pathogen. 2. The SELEX Execution: Performing multiple (usually 8-15) rounds of the selection process under optimized conditions (buffer, temperature, washing stringency). 3. Next-Generation Sequencing (NGS) & Bioinformatics: After the final rounds, the enriched pool is sequenced using NGS. Bioinformatic analysis identifies sequence…

    2026-01-16
  • Antibody Aptamer Screening Service

    What is an Antibody Aptamer Screening Service? It is a specialized contract research service where a biotechnology company uses SELEX (Systematic Evolution of Ligands by EXponential Enrichment) or advanced variations of it to discover and develop aptamers that bind with high affinity and specificity to a target antibody. Antibody: A large, Y-shaped protein produced by the immune system to identify and neutralize pathogens. Aptamer: A short, single-stranded DNA or RNA oligonucleotide (or a modified derivative) that folds into a specific 3D structure, enabling it to bind to a target molecule with antibody-like specificity. Often called "chemical antibodies." The goal of the service is to provide clients with synthetic, recombinant-like binding molecules as alternatives or complements to traditional monoclonal antibodies. Why Screen for Aptamers Against Antibodies? Aptamers offer distinct advantages, making them attractive for various applications: Anti-Drug Antibody (ADA) Detection: Develop aptamer-based assays to detect and quantify ADAs in clinical trials for biotherapeutics. Diagnostic Tools: Create aptamer sensors (aptasensors) to detect specific antibody biomarkers for diseases (e.g., autoantibodies in autoimmune disorders). Therapeutic Neutralization: Discover aptamers that can bind and neutralize pathological antibodies (e.g., in autoimmune diseases like lupus or myasthenia gravis). Purification & Pull-Down: Use aptamers as ligands in chromatography or in assays to capture and isolate specific antibodies from complex…

    2026-01-14
  • Aptamer Screening Service for Drug Discovery

    What is an Aptamer? Aptamers are single-stranded DNA or RNA oligonucleotides that fold into specific 3D shapes, enabling them to bind to target molecules (proteins, small molecules, cells, viruses) with high affinity and specificity, similar to antibodies. They are often called "chemical antibodies." Why Use Aptamer Screening Services in Drug Discovery? Efficiency: Outsourcing to experts with specialized platforms (SELEX) accelerates discovery. Cost-Effectiveness: Avoids capital investment in complex SELEX and NGS infrastructure. Expertise: Leverages specialized knowledge in oligonucleotide chemistry, bioinformatics, and target biology. Focus: Allows internal teams to concentrate on downstream therapeutic development. Core Components of an Aptamer Screening Service A full-service provider typically offers an end-to-end pipeline: 1. Project Design & Target Preparation Consultation: Defining the target (recombinant protein, cell surface marker, whole cell), desired affinity (nM-pM), and specificity (e.g., against homologs). Counter-SELEX Strategy: Planning to eliminate binders to non-desired epitopes or related targets to ensure high specificity. 2. In Vitro Selection (SELEX) The core technology is SELEX (Systematic Evolution of Ligands by EXponential enrichment). Advanced variants are used for complex targets: Protein-SELEX: For purified recombinant proteins. Cell-SELEX: For membrane proteins in their native conformation on live cells; identifies aptamers for diseased vs. healthy cells. Tissue-SELEX: For even more complex biological environments. Capture-SELEX: For small molecules that are difficult to immobilize. High-Throughput SELEX (HT-SELEX): Uses NGS early…

    2026-01-13
  • Aptamer Screening Service for Protein Antibody Receptors

    What is an Aptamer Screening Service? It is a contract-based service where a specialized laboratory uses Systematic Evolution of Ligands by EXponential enrichment (SELEX) to discover single-stranded DNA or RNA molecules (aptamers) that bind with high affinity and specificity to your target molecule (e.g., a protein, an antibody's constant region, or a cell-surface receptor). Core Service Components A full-service provider typically offers an end-to-end pipeline: 1. Project Design & Target Preparation Consultation: Defining the goal (e.g., detection, inhibition, delivery). Target Characterization: Ensuring the target (purified protein, antibody, receptor-expressing cells) is properly formatted and validated. Negative Selection/Counter-SELEX: Designing the screening to avoid binders to similar, non-target structures (e.g., the Fc region of a different antibody isotype, a common cell surface protein). 2. Library & Selection (The Core SELEX Process) Library Design: Using a diverse random oligonucleotide library (typically 10^14 - 10^15 unique sequences). Selection Method: The choice of method is critical and depends on the target: Protein SELEX: For purified, soluble targets immobilized on beads or in solution. Cell-SELEX: For membrane receptors in their native conformation on live cells. Excellent for discovering aptamers to unknown receptor complexes. Capture-SELEX/Toggle-SELEX: For difficult-to-immobilize targets or to increase stringency. In Vivo SELEX: For discovering aptamers that home to specific tissues in vivo. Iterative Rounds: Typically 8-15 rounds of…

    2026-01-12
  • Aptamer Screening Service-Targeting Protein Cytokines

    What is an Aptamer? An aptamer is a short, single-stranded DNA or RNA oligonucleotide that folds into a specific 3D structure, allowing it to bind to a target molecule (like a cytokine) with high affinity and specificity, akin to a monoclonal antibody. Why Target Cytokines with Aptamers? Cytokines are key signaling proteins in immune and inflammatory responses. Dysregulation is implicated in diseases like: Autoimmune disorders: Rheumatoid arthritis, psoriasis, inflammatory bowel disease. Cancer: Tumor microenvironment signaling. Cytokine Storms: Severe COVID-19, sepsis. Neurological diseases. Aptamers offer advantages over traditional antibody-based therapies: High Specificity: Can distinguish between closely related cytokine isoforms or conformational states. Controlled Synthesis: Chemically produced, no batch-to-batch variation. Modifiability: Easily conjugated with drugs, fluorophores, or nanoparticles. Low Immunogenicity: Less likely to cause an immune response. Stability: Generally more stable than proteins. The Aptamer Screening Service Workflow (SELEX) A professional service will manage the entire SELEX (Systematic Evolution of Ligands by EXponential Enrichment) process. Here’s a typical pipeline: Phase 1: Project Design & Target Preparation Consultation: Define the goal—neutralization, detection, or delivery. Target Selection: Which cytokine? (e.g., TNF-α, IL-6, IL-1β, IFN-γ). Requires a high-purity, bioactive protein. Services often help with recombinant expression/purification if needed. Library Design: A vast random-sequence oligonucleotide library (10^14-10^15 unique sequences) is the starting point. Libraries can be DNA, RNA, or contain modified…

    2026-01-12
  • Aptamer Screening Service-Protein-Specific Selection

    What is an Aptamer? An aptamer is a short, single-stranded DNA or RNA oligonucleotide that binds to a specific target molecule (like a protein) with high affinity and specificity. They are often called "chemical antibodies" but offer advantages like smaller size, chemical stability, and in-vitro generation. The Core Service: SELEX (Systematic Evolution of Ligands by EXponential Enrichment) The standard method for aptamer screening is SELEX. A specialized service will manage this entire iterative, high-complexity process for you. General SELEX Workflow: Target Preparation & Immobilization: Your service provider will prepare your purified protein. It is often immobilized on a solid support (beads, column, plate) to separate bound from unbound sequences. Incubation with Library: A vast, random synthetic oligonucleotide library (10^13 - 10^15 unique sequences) is incubated with the target. Partitioning: Weak or non-binding sequences are washed away. Tightly bound aptamers are retained. Elution & Amplification: The bound sequences are eluted and amplified by PCR (for DNA) or RT-PCR (for RNA). Stringency & Counter-SELEX: Subsequent rounds introduce increased washing stringency and incubation with non-target molecules (e.g., similar proteins, immobilization matrix) to filter out non-specific binders. This is crucial for specificity. Cloning & Sequencing: After 8-15 rounds, the enriched pool is cloned and sequenced to identify individual candidate aptamers. Characterization &…

    2026-01-12
  • Aptamer Screening Service-Protein SELEX

    What is Protein SELEX? SELEX (Systematic Evolution of Ligands by EXponential Enrichment) is an iterative, in vitro process used to discover aptamers—single-stranded DNA or RNA molecules that bind to a specific target (like a protein) with high affinity and specificity. Protein SELEX specifically refers to using a purified protein as the target to isolate aptamers against it. These aptamers are often called "chemical antibodies" due to their similar binding function. Core Workflow of a Protein SELEX Service A professional service will manage this entire complex process, typically involving the following stages: 1. Project Design & Consultation Target Characterization: Discussing the target protein's properties (size, purity, stability, domains, post-translational modifications). Selection Strategy: Choosing the right SELEX variant (e.g., Nitrocellulose filter, Magnetic bead, Capillary Electrophoresis, or Cell-SELEX for membrane proteins). Defining counter-selection steps to avoid binders to unwanted tags or impurities. Library Design: Using a standard or custom random oligonucleotide library (e.g., 40-60 random nucleotides flanked by primer sites). 2. The SELEX Cycle (Repeated 8-15 Rounds) mermaid graph TD A[Start: ssDNA/RNA Library<br>~10^15 unique sequences] --> B{Incubation with<br>Target Protein}; B --> C[Partition: Separate<br>Bound from Unbound Sequences]; C --> D[Elution: Recover<br>Bound Sequences]; D --> E[Amplification:<br>PCR (DNA) or RT-PCR (RNA)]; E --> F[Purification:<br>Regenerate ssDNA/RNA for next round]; F --> G{Enrichment<br>Sufficient?}; G -- No…

    2026-01-08